Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lilly's CYRAMZA Gains Sixth FDA Approval | Contract Pharma

What are you searching for?

Sign in
Breaking News

Lilly’s CYRAMZA Gains Sixth FDA Approval

CYRAMZA plus erlotinib is the first FDA-approved anti-VEGFR/EGFR TKI combination therapy for metastatic EGFR-mutated NSCLC.

By: Contract Pharma

Contract Pharma Staff

Eli Lilly and Co. received approval from the U.S. FDA for CYRAMZA (ramucirumab injection, 10 mg/mL solution), in combination with erlotinib, for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. With this approval, CYRAMZA has now received six FDA approvals to treat certain types of lung, liver, stomach and colorectal cancers.

CYRAMZA plus erlotinib is the first and only FDA-approved anti-VEGFR/EGFR TKI combination therapy for metastatic EGFR-mutated NSCLC. This approval is based on the efficacy and safety from the global, randomized, placebo-controlled Phase 3 RELAY trial in which CYRAMZA, a VEGF receptor 2 antagonist, in combination with erlotinib, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to placebo in combination with erlotinib (19.4 months compared to 12.4 months). The PFS treatment effect was consistent across exon 19 and exon 21 subgroups.

Fifty percent of people with NSCLC present with advanced or metastatic disease at diagnosis. The five-year survival rate for metastatic NSCLC patients is six percent. In the U.S., it is estimated that approximately 15 percent of people diagnosed with NSCLC have an EGFR mutation.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics